Immediate Impact

4 from Science/Nature 55 standout
Sub-graph 1 of 24

Citing Papers

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout
Suicide and self-harm
2022 Standout
2 intermediate papers

Works of Alan Green being referenced

CLOZAPINE VS. RISPERIDONE FOR PEOPLE WITH FIRST EPISODE SCHIZOPHRENIA AND CO-OCCURRING CANNABIS USE DISORDER
2010
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial
2003

Author Peers

Author Last Decade Papers Cites
Alan Green 121 37 270 133 37 621
Danielle Charbonneau 80 13 89 162 17 650
Lisa Lee 39 18 87 152 33 615
Anja Kraus 215 8 196 269 28 641
Richard Lucas 11 16 115 329 39 603
Marco Tommasi 39 14 110 281 67 693
Salvador Contreras 19 4 263 87 42 681
Cheng Li 154 28 85 72 38 667
Kerem Coşkun 178 13 142 218 49 574
Simon Boag 22 6 86 248 55 602
Tanya Tran 53 3 162 238 29 731

All Works

Loading papers...

Rankless by CCL
2026